| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5945416 | LILLY | Method for treating pain |
Mar, 2017
(7 years ago) | |
| US6960577 | LILLY | Combination therapy for treatment of refractory depression |
Nov, 2017
(6 years ago) | |
Symbyax is owned by Lilly.
Symbyax contains Fluoxetine Hydrochloride; Olanzapine.
Symbyax has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Symbyax are:
- US5945416
- US6960577
Symbyax was authorised for market use on 09 April, 2007.
Symbyax is available in capsule;oral dosage forms.
Symbyax can be used as symbyax is indicated for the acute treatment of treatment resistant depression in adults.
The generics of Symbyax are possible to be released after 01 November, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-593) | Mar 19, 2012 |
| M(M-142) | Oct 10, 2017 |
| New Patient Population(NPP) | Jul 26, 2016 |
Drugs and Companies using FLUOXETINE HYDROCHLORIDE; OLANZAPINE ingredient
Market Authorisation Date: 09 April, 2007
Treatment: Symbyax is indicated for the acute treatment of treatment resistant depression in adults
Dosage: CAPSULE;ORAL
SYMBYAX family patents
